Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Henan Taloph Pharmaceutical Stock Co Ltd Announces FY 2012 Net Profit Outlook


Sunday, 20 Jan 2013 07:00pm EST 

Henan Taloph Pharmaceutical Stock Co Ltd announced that it expects its net profit for fiscal year (FY) 2012 to increase by more than 50%, compared to the net profit of FY 2011 (RMB 12.75 million). The Company cited the increased sales income and gross profit rate as the main reason for the forecast. 

Company Quote